New Malaria Vaccine Cuts Child Deaths by 75% in Landmark African Trial
Photo: Magdalena Kula Manchee / Unsplash
A next-generation malaria vaccine has achieved a 75% reduction in severe disease and death among children under five in a multi-country trial spanning Ghana, Kenya, and Malawi. The R21/Matrix-M vaccine, developed through a partnership between Oxford University and the Serum Institute of India, is now being rolled out across 18 sub-Saharan African nations. Health officials describe the milestone as one of the most significant advances in infectious disease prevention in a generation.
A next-generation malaria vaccine has achieved a 75% reduction in severe disease and death among children under five in a multi-country trial spanning Ghana, Kenya, and Malawi. The R21/Matrix-M vaccine, developed through a partnership between Oxford University and the Serum Institute of India, is now being rolled out across 18 sub-Saharan African nations. Health officials describe the milestone as one of the most significant advances in infectious disease prevention in a generation.